Last reviewed · How we verify
NCT05609656: ELI
Electroporation and Immunotherapy in Metastatic Colorectal Cancer
Phase 2 trial testing Irreversible electroporation in Metastatic Colorectal Cancer in 4 participants. Terminated before completion.
8 April 2024
Quick facts
| Lead sponsor | Ismail Gögenur |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 4 |
| Start date | 26 January 2023 |
| Primary completion | 8 April 2024 |
| Estimated completion | 2 May 2024 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Irreversible electroporation
- Calcium electroporation — full drug profile →
- Pembrolizumab (pembrolizumab) — full drug profile →
Conditions studied
- Metastatic Colorectal Cancer — all drugs for Metastatic Colorectal Cancer →
Sponsor
Ismail Gögenur — full company profile →
Who can join
18 and older, any sex, with Metastatic Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The trial is designed as an investigator initiated prospective phase 2 study in patients with metastatic pMMR colorectal cancer (CRC) to determine the safety and efficacy of calcium electroporation (CaEP) performed concurrently with irreversible electroporation (IRE) followed by a PD-1 inhibitor (pembrolizumab).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Mismatch repair-proficient tumor footprints in the sands of immune desert: mechanistic constraints and precision platforms.
Majumder B, Nataraj NB, Maitreyi L, Datta S. · · 2024 · cited 3× · PMID 39100682 · DOI 10.3389/fimmu.2024.1414376
Verify or expand the search:
- PubMed search for NCT05609656
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Irreversible electroporation
Trials testing the same drug.
- NCT07306273 — IRE Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Th · Phase 2 · recruiting
- NCT06677762 — Irreversible Electroporation Ablation Combined With Anti-PD(L)1 Therapy for Locally Advanced Pancreatic Cancer · not yet recruiting
- NCT06185556 — COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Per · Phase 2, PHASE3 · recruiting
- NCT04717687 — Pilot Study on the Evaluation of Irreversible Electroporation Technique in Infiltrating Perihilar Cholangiocarcinoma · NA · withdrawn
- NCT04404647 — Irreversible Electroporation of Unresectable Liver Tumors · NA · withdrawn
Other recruiting trials for Metastatic Colorectal Cancer
Currently open trials in the same condition.
- NCT07416552 — A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC) · Phase 1 · recruiting
- NCT07314294 — Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients · Phase 2 · recruiting
- NCT06856837 — - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Misma · Phase 2 · recruiting
- NCT06959550 — Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorect · Phase 2 · recruiting
- NCT06808685 — Real World Multicenter National Study to Evaluate the Effectiveness and Safety of Biosimilar Bevacizumab Elovie · recruiting
Other Ismail Gögenur trials
Trials by the same sponsor.
- NCT07409844 — Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer · Phase 2 · not yet recruiting
- NCT05740969 — Gene and Protein Expression Profiles After Treatment of Actinic Keratoses · Phase 2 · unknown
- NCT05740137 — Adenoma Detection Rate in Artificial Intelligence-assisted Colonoscopy · NA · completed
- NCT05754229 — Accuracy of Real Time Characterization in Artificial Intelligence-assisted Colonoscopy · NA · unknown
- NCT05435053 — Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05609656 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ismail Gögenur
- Last refreshed: 3 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05609656.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing